Applications of AI in healthcare, including medical diagnostics, drug discovery, patient care solutions, and biotechnology research.
CerraCap Ventures has invested in Nephronomics, an AI bio precision medicine company developing data driven approaches to kidney disease research and drug discovery. The partnership aims to advance precision therapies using one of the largest renal datasets in the world.
Six NHS Trusts in north central London have signed a GBP 15.6 million contract with Sectra to consolidate their imaging systems into a single cloud environment using Sectra One Cloud, improving cybersecurity and collaboration across hospitals.
Texas Biomedical Research Institute is developing new approach methodologies that combine AI modeling, organoids, and organ-on-a-chip systems to improve drug safety and disease research.
Oracle Health has been designated as a Centers for Medicare and Medicaid Services Aligned Network and introduced a digital identity verification and check-in solution that integrates with healthcare providers’ electronic health record workflows.
Pulnovo Medical has completed a $100 million strategic financing round led by Medtronic, with participation from existing and new investors. The two companies also signed a commercial agreement to explore future marketing opportunities for Pulnovo's pulmonary artery denervation system.
Nanostics has published a peer-reviewed study validating its ClarityDX Prostate AI models for predicting aggressive prostate cancer, showing high accuracy across multiple configurations and potential to reduce unnecessary biopsies.
Mitate Zepto Technica has joined the Japan Science and Technology Agency’s Next-Generation Edge AI Semiconductor R&D Program as a social implementation partner, focusing on genome analysis acceleration through its RASEN ASIC platform.
Bracco Imaging and NYU Langone Health have signed a multi-year Master Research Agreement to advance innovation in MRI, CT, ultrasound, and AI-enabled PET/CT imaging technologies.
Immunofoco presented new preclinical data for its in vivo BCMA-targeting CAR T candidate IMV102 at the AACR Annual Meeting 2026, showing durable tumor control and favorable safety in multiple myeloma models.
OpenAI has launched GPT‑Rosalind, a specialized AI model designed to support research in biology, drug discovery, and translational medicine. The model aims to help scientists accelerate early-stage discovery and improve experimental workflows through advanced reasoning and tool integration.
Ryght AI has introduced RyghtSites.com, a free AI-powered search engine that enables pharmaceutical companies and CROs to find and rank clinical research sites across 192 countries.
EmpiRx Health has introduced an Infusion Therapy Management solution designed to lower costs by moving infusion therapies from medical to pharmacy benefits and enhancing clinical oversight through its Medication Optimization model.
PrecisionLife and Ovation.io have agreed to co-develop laboratory tests and a consumer DNA test to predict individual responses to GLP-1 drugs, with commercial launch planned for the second half of 2026.
Wobble Genomics will present new research at the AACR Annual Meeting 2026 showcasing full-length mRNA sequencing from blood samples to support antibody-drug conjugate therapy selection in breast cancer.
Cepheid and Oxford Nanopore Technologies have announced the second phase of their collaboration to develop a genomic workflow for rapid bacterial and fungal pathogen identification in infectious disease research.
Axxess will host its 2026 AGILE conference May 4–6 in Dallas, focusing on responsible AI adoption, oversight, and leadership training for home health and hospice executives.
Xtalks will host a free webinar on April 30, 2026, focusing on how molecular reclassification, minimal residual disease, and AI are transforming precision hematology. Experts from NeoGenomics and Fortrea will discuss AI-driven diagnostics and molecular endpoints in cancer research.
Sunbound has launched sunbound.ai, an AI-driven Revenue OS for senior living operators, following a year in which it tripled annual payment volume to over $1 billion and expanded its leadership team.
Caristo Diagnostics has appointed Stephen M. Deitsch as its new Chief Executive Officer, effective immediately. Deitsch, previously CFO of OrganOx, succeeds Frank Cheng, who will become Chief Operating Officer.
Briya announced that its global data network now includes over 120 million patient records, expanding coverage to Latin America and the UK to support AI-driven medical research through its Briya AIRE research engine.
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
